The existing strategy to alleviate diabetes mainly involves oral anti-hyperglycemic agents (biguanides, sulfonylureas, glucagon-like peptide-1 (GLP-1) receptor agonists, insulin sensitizers, α-glucosidase inhibitors, and thiazolidinedione) (4), which may be accompanied by many side effects (5). This evidence concerns the gene INS and diabetes mellitus.